Table 2.
Predictor | 12 months prefracture OR (95 % CI) |
P value | 24 months prefracture OR (95 % CI) |
P value |
---|---|---|---|---|
Demographic and general health characteristics | ||||
History of falls | 6.67 (6.03–7.37) | <0.0001 | 4.43 (4.09–4.80) | <0.0001 |
Every additional decade after age 50 years | 2.00 (1.98–2.03) | <0.0001 | 1.97 (1.94–2.00) | <0.0001 |
Comorbidities | ||||
CNS disease | 1.41 (1.30–1.52) | <0.0001 | 1.34 (1.25–1.43) | <0.0001 |
Psychoses | 1.37 (1.26–1.48) | <0.0001 | 1.34 (1.25–1.44) | <0.0001 |
Alzheimer’s disease | 1.35 (1.22–1.50) | <0.0001 | 1.25 (1.14–1.37) | <0.0001 |
General health status measures | ||||
DCIa | ||||
≥4 | 1.46 (1.35–1.59) | <0.0001 | 1.49 (1.38–1.62) | <0.0001 |
3 | 1.40 (1.31–1.50) | <0.0001 | 1.42 (1.32–1.52) | <0.0001 |
2 | 1.26 (1.19–1.32) | <0.0001 | 1.29 (1.22–1.36) | <0.0001 |
1 | 1.16 (1.12–1.20) | <0.0001 | 1.17 (1.13–1.22) | <0.0001 |
Concomitant medications | ||||
Narcotics | 2.11 (2.05–2.18) | <0.0001 | 1.85 (1.79–1.92) | <0.0001 |
Antidepressants—SSRIs | 1.47 (1.41–1.52) | <0.0001 | 1.41 (1.36–1.46) | <0.0001 |
Muscle relaxants | 1.40 (1.34–1.47) | <0.0001 | 1.29 (1.25–1.35) | <0.0001 |
Tranquilizers | 1.29 (1.18–1.40) | <0.0001 | 1.24 (1.15–1.34) | <0.0001 |
Antidepressants—other | 1.27 (1.21–1.33) | <0.0001 | 1.22 (1.16–1.27) | <0.0001 |
Anti-Parkinson | 1.24 (1.15–1.35) | <0.0001 | 1.20 (1.11–1.29) | <0.0001 |
Antidepressants—tricyclics | 1.09 (1.02–1.17) | 0.0119 | – | NS |
Sedatives and sleep aids, excluding benzodiazepines | 1.05 (1.00–1.11) | 0.0376 | 1.08 (1.03–1.12) | 0.0010 |
Mobility/frailty | ||||
Wheelchair use | 1.79 (1.61–2.00) | <0.0001 | 1.80 (1.64–1.97) | <0.0001 |
Mobility impairment | 1.46 (1.41–1.51) | <0.0001 | 1.39 (1.34–1.43) | <0.0001 |
Home healthcare | 1.24 (1.16–1.34) | <0.0001 | 1.20 (1.13–1.28) | <0.0001 |
Nursing home | 1.19 (1.12–1.28) | <0.0001 | 1.19 (1.13–1.26) | <0.0001 |
Risk factors with OR > 1 and significant (P < 0.05) included on table
CNS central nervous system, DCI Deyo-Charlson Comorbidity Index, NS nonsignificant, OR odds ratio, SSRI selective serotonin reuptake inhibitor
aReference group: 0